Vienna Heart Center leverages
Marizyme’s DuraGraft as the Standard-of-Care in Patients Undergoing Coronary
Artery Bypass Surgery
#Cardiac #cardiologist #doctor #cardio #cardiovascular #ECG #HeartNews #healthcare #medicaltechnology
A global
biotechnology company developing products to reduce the burden of
ischemia-reperfusion injury in tissue grafting, organ transplant, and other
surgical indications, today announced as of August 2020 the Vienna Heart Center
North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the
company's flagship product, DuraGraft® as the standard-of-care for flushing and
storage of the saphenous vein grafts from harvesting through grafting in
Coronary Artery Bypass Grafting (CABG) patients.
Vienna Heart Center North
Floridsdorf, an internationally recognized leader, is Austria's latest
super-specialty center. Opening in 2019, it is one of Europe's most modern
Centers. The hospital has a Heart and Vascular Center with a focus on aortic
procedures and minimally invasive cardiovascular procedures and all techniques
of CABG. The center performs approximately 500 CABG surgeries per year and is
part of the ongoing DuraGraft EU Multicenter Registry to Assess Outcomes in
CABG Patients: Treatment of Vascular Conduits with DuraGraft to Evaluate the
Safety and Performance of DuraGraft (VASC). Based on the performance of
DuraGraft in improving patient outcomes, the Cardiac Surgery Center at Vienna
Heart Center North Floridsdorf in August 2020 recognized DuraGraft as the
standard-of-care for CABG surgeries.
"We have seen encouraging
evidence that reinforces the importance of appropriate graft treatment during
surgery and the role of DuraGraft in significantly improving outcomes in all
patients. Additionally, we have observed significant myocardial protection
utilizing DuraGraft during CABG, where we have implemented a recent
study," said Associate Professor Priv. Doz. Dr. Bernhard Winkler at Vienna
Heart Center North Floridsdorf.
The Chief of Cardiac Surgery at the
hospital, Prof. Dr. Martin Grabwenwöger, said, "Saline, blood and buffered
solutions have long been considered the standard-of-care for CABG surgery;
however, studies have shown that DuraGraft outperforms its predecessors. We are
thrilled to have DuraGraft as our new standard-of-care for graft treatments
during CABG Surgery."
"The endothelial damage
inhibitor, DuraGraft, has shown promising results in several preclinical
studies and large-scale clinical investigations to adequately protect and
preserve vascular conduits and in improving clinical outcomes. Therefore, its
use as standard-of-care for vascular conduit storage and prevention of ischemic
injury is not surprising," said Prof. Dr. Maximilian Emmert from the
German Heart Center Berlin, Germany and PI of the VASC Registry.
Dr. Neil J. Campbell, Chief
Executive Officer of Marizyme, stated, "Clinical evidence generated by
independent researchers around the world have shown that DuraGraft improves
CABG clinical outcomes resulting in DuraGraft providing a value proposition to
patients, cardiac centers and healthcare systems worldwide. We at Marizyme are
extremely excited to offer this product to CABG patients."
About CABG and DuraGraft When
patients with heart disease undergo CABG surgery, free vein or arterial grafts
harvested from the leg, arm or chest are frequently used to bypass occluded
coronary arteries; about 90% of CABG surgeries use at least one free vein
graft. In most cases, in the time between harvesting and bypass grafting, the
free graft is stored in saline or autologous blood which do not protect the
graft from ischemic injury thereby increasing the risk of ischemia-reperfusion
injury and graft disease and ultimate failure leading to post-CABG myocardial
infarction and the need for repeat revascularization procedure.
DuraGraft is a CE-marked product
that protects vascular grafts against ischemic injury and is the only product
approved for graft protection and preservation during bypass and other vascular
surgeries. DuraGraft protects graft tissue from harvesting through anastomosis
and is used during vascular surgery (including CABG) as a treatment to maintain
the structural and functional integrity of isolated vascular grafts. The use of
DuraGraft is associated with the reduction of post-CABG complications
associated with graft disease and failure: Myocardial Infarction, Repeat
Revascularization, and MACE.
Clinical studies in more than 3,000
patients support the long-term safety and efficacy of DuraGraft. The use of
DuraGraft in CABG surgery is associated with statistically significant lower
risks for clinical complications following CABG; 45% reduction in non-fatal
myocardial infarction (MI) (p <.0001), 35% reduction in repeat
revascularization (p=0.037), and 19% reduction of MACE (a composite of all
major adverse cardiac events)
About Vienna Heart Center North
Floridsdorf The latest super-specialty heart center, one of the most modern
centers in Europe, 800 beds with a large unit together cardio-vascular, interventional
radiology, cardiology.
About Marizyme, Inc. Marizyme, Inc.
is a development-stage company dedicated to the commercialization of therapies
that address the urgent need relating to higher mortality and costs in the
acute care space. Specifically, Marizyme will focus its efforts on developing
and acquiring treatments for those diseases. Through its recent acquisition of
Somahlution it has acquired products and product candidates that reduce the
burden of ischemia reperfusion injury in tissue grafting, organ transplant, and
other surgical indications. The company's flagship product, DuraGraft, is a
vascular graft treatment that improves clinical outcomes by reducing the
incidence of complications associated with graft failure. DuraGraft enhances CABG
surgical outcomes by significantly reducing major cardiac events such as repeat
revascularization and myocardial infarction. For More Information
visit: https://heartcongress.healthconferences.org
Forward-Looking Statements This
press release may contain certain forward-looking statements, including those
relating to the Marizyme's product development, clinical and regulatory
timelines, market opportunity, competitive position, possible or assumed future
results of operations, business strategies, potential growth opportunities and
other statements that are predictive in nature. The Company has made every
reasonable effort to ensure the information and assumptions on which these
statements are based are current, reasonable and complete. However, a variety of
factors, many of which are beyond the Company's control, affect the Company's
operations, performance, business strategy and results and there can be no
assurances that the Company's actual results will not differ materially from
those indicated herein. Additional written and oral forward-looking statements
may be made by the Company from time to time. Forward-looking statements may be
identified by the use of forward-looking expressions, including, but not
limited to, "expect," "anticipate," "intend,"
"plan," "believe," "estimate,"
"potential," "predict," "project,"
"should," "would" and similar expressions and the negatives
of those terms. These statements relate to future events or our financial
performance and involve known and unknown risks, including those risks set
forth in the Company's risk factor disclosure in its Registration Statement on
Form 10K filed with the Securities and Exchange Commission (SEC File No.
000-53223), uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking
statements. Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.
Contact: cardionheart@gmail.com
